Compare Cassava Sciences Inc (FLNA) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Alphabet Inc Class A — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Alphabet Inc Class A trades at $355.63 (market cap $4.52T). The key difference: Alphabet Inc Class A is far larger — about 85058.3× Cassava Sciences Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | GOOGL | |
|---|---|---|
Market Cap | $53.14M | $4.52T |
Sector | Health | Media |
52-Week High | $4.64 | $402.62 |
52-Week Low | $1.09 | $182.97 |
Enterprise Value | -$33.43M | $4.49T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Alphabet (GOOGL) trades at $354.37, down 1.43% on the day, amid a bullish technical setup with strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 estimate. Financial health is solid, with 2025 revenue of $402.84 billion and net income of $132.17 billion, reflecting a net margin of 32.8%. Positive news flow highlights AI-driven growth and strategic partnerships.
Outlook remains positive given earnings momentum, AI expansion, and a consensus price target of $431.78 implying 22% upside. Risks include antitrust scrutiny and tech sector volatility. Institutional sentiment is strongly bullish with 85% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
